Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Elara MD vs Maves

Elara MD
Graded #466

Lower grade

vs+18.299999999999997
Maves
Graded #89

Higher grade

The verdict

Maves takes it — 71.8/100 to 53.5/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +44
40
84
Dose & formulationMaves +11
54
65
Clinical oversightMaves +13
63
76
Labs & monitoringEven
52
52
FulfillmentMaves +21
66
87
Contract termsEven
55
55
Elara MD · left barMaves · right bar

The numbers

MetricElara MDMaves
WeighScore53.5/10071.8/100
GradeCC
Scorecard rank#466#89
Semaglutide$249/mo (0.2 mg dose, compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$349/mo (2.0 mg dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Elara MD

Graded #466 · C

Strengths

  • Dose-banded monthly pricing published on-site ($249–$649/mo across tiers)
  • Both a semaglutide-range and a tirzepatide-range (GLP-1/GIP) option, plus microdosing
  • Medication included in the monthly price with free fast shipping when prescribed
  • Broad reach claimed (over 40 states)

Where it loses points

  • Molecules not named on-site (only 'Personalized GLP-1') — compounded status is inferred
  • No FDA compounded-medication disclaimer published
  • No named compounding pharmacy partner — prescriptions are patient-directed
  • LegitScript certification, medical director, and full state list not disclosed
  • Pricier than several compounded competitors
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard